VIDEO: RGX-314 shows positive results for diabetic retinopathy at 1 year
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher Dhoot, MD, shares 1 year results from the phase 2 ALTITUDE trial investigating RGX-314 gene therapy for the treatment of diabetic retinopathy.
According to Dhoot, the two dose levels of RGX-314 (Regenxbio, AbbVie) that were studied were well tolerated and demonstrated improvement in patient Diabetic Retinopathy Severity Scale score compared to a control group.
“I think the results of this trial are compelling,” he said. “Potentially having a one-time gene therapy in-office injection can help change the paradigm in patients with moderately severe and severe diabetic retinopathy, potentially resulting in improvements of vision for many years to come for this population.”
Collapse
Dhoot DS. Suprachoroidal delivery of investigational ABBV-RGX-314 for diabetic retinopathy: The phase 2 ALTITUDE study dose levels 1 and 2: One year results. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Read more about
Click Here to Manage Email Alerts